55737-66-1

Basic information

• Product Name: 2-NITRO-4-METHOXYCARBONYL BENZOIC ACID
• Synonyms: 2-NITRO-4-METHOXYCARBONYL BENZOIC ACID;RARECHEM AL BE 0920;2-Nitroterephthalic acid 4-methyl ester, 97%;4-methoxycarbonyl-2-nitrobenzoic acid
• CAS NO: 55737-66-1
• Molecular Formula: C₉H₇NO₆
• Molecular Weight: 225.15
• Mol File: 55737-66-1.mol

Chemical Properties

• Melting Point: 133-135°C
• Boiling Point: 393.5°C at 760 mmHg
• Flash Point: 191.8°C
• Appearance: /
• Density: 1.486g/cm³
• Vapor Pressure: 6.71E-07mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: Sealed in dry,Room Temperature
• Water Solubility: Insoluble in water.
• CAS DataBase Reference: 2-NITRO-4-METHOXYCARBONYL BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-NITRO-4-METHOXYCARBONYL BENZOIC ACID(55737-66-1)
• EPA Substance Registry System: 2-NITRO-4-METHOXYCARBONYL BENZOIC ACID(55737-66-1)

Safety Data

• Hazardous Substances Data: 55737-66-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Nitro-4-Methoxycarbonyl Benzoic Acid is used as a precursor or an intermediate compound for various chemical reactions and processes. Its unique functional groups allow it to participate in a wide range of organic synthesis, making it a valuable component in the creation of new compounds and materials.
Used in Pharmaceutical Industry:
2-Nitro-4-Methoxycarbonyl Benzoic Acid is used as a building block in the development of pharmaceuticals. Its specific functional groups and reactivities make it a promising candidate for the synthesis of new drug molecules, potentially leading to the discovery of novel therapeutic agents.
Used in Allied Fields:
2-Nitro-4-Methoxycarbonyl Benzoic Acid is also used in other allied fields, such as materials science and chemical research. Its unique properties and reactivities contribute to the advancement of knowledge and the development of new applications in these areas.

InChI:InChI=1/C9H7NO6/c1-5(11)16-6-2-3-7(9(12)13)8(4-6)10(14)15/h2-4H,1H3,(H,12,13)

Upstream product

• 67-56-1 methanol 
• 610-29-7 2-nitroterephthalic acid 

Downstream Products

• 480391-09-1 methyl 4-[5-(4-t-butylphenyl)-1,3,4-oxadiazol-2-yl]-3-nitrobenzoate 
• 480391-01-3 methyl 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzoate 
• 480391-02-4 methyl 3-nitro-4-[3-(4-trifluoromethylphenyl)-1,2,4-oxadiazol-5-yl]benzoate 
• 480391-08-0 methyl 3-nitro-4-[5-(4-trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl]benzoate 
• 89950-93-6 methyl 4-(hydroxymethyl)-3-nitrobenzoate 
• 51885-90-6 methyl 4-(chloromethyl)-3- nitrobenzoate 
• 1374785-44-0 N-(4-chlorophenyl)-3-(3,6-dichlorobenzo[b]thiophene-2-carboxamido)terephthalamic acid methyl ester 
• 1374785-43-9 4-(4-chlorophenylcarbamoyl)-3-(3,6-dichlorobenzo[b]thiophene-2-carboxamido)benzoic acid 
• 1374779-43-7 C₁₅H₁₃ClN₂O₃ 
• 1373278-36-4 methyl 2-(5-tert-butoxy-5-oxopentyl)-4-oxo-3-p-tolyl3,4-dihydroquinazoline-7-carboxylate 
• 1373278-34-2 2-(6-tert-butoxy-6-oxohexanamido)-4-(methoxycarbonyl)benzoic acid 
• 1108745-71-6 2-nitro-terephthalic acid 1-tert-butyl ester 4-methyl ester 
• 183431-09-6 methyl 4-(methylamino)carbonyl-3-nitrobenzoate 
• 138569-09-2 Methyl 3-nitro-4-(thiazol-2-yl)benzoate 

Relevant articles and documents

NEUROTRYPSIN INHIBITORS

The invention relates to acylamino-phthalic acid amides and related compounds of formula (I) wherein A is -CONR3R4,-NR5COR6, -NHR7, -OR8, -mR9, -CH2NRI0R11, -(CH2)2-R12, -CH=CH-R12, -C=C-R12, optionally substituted phenyl, optionally substituted thiophenyl, or optionally substituted 1,2,3-triazol-4-yl, W is hydrogen, hydroxy or carboxymethoxy, Y is carboxy, methoxycarbonyl or 2H-tetrazol-5-yl, and the various substituents R have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer?s disease, and as cognitive enhancers.

AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compounds of the instant invention may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compounds of the invention may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.

Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design

A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4- (acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10-6 M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase in a manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.

Substituted benzene derivatives useful as neuraminidase inhibitors

A compound of the Formula (I): STR1 or pharmaceutically-suitable salts or prodrug forms thereof, wherein: n is 0-1; m is 0; p is 0-1; R1 is --CO2 H; R2 is selected from the group consisting of H, --OH, and --NH2 ; R3 is H; R4 is --C(O)NHR8 ; R5 is --NHC(R6)NH2 R6 is selected from the group consisting of =NH, =NOH, =NCN, =O, and =S; and R8 is selected from the group consisting of C1 -C4 linear or branched alkyl substituted with 0-3 halogens on each carbon.

Oligoanthranilamides. Non-peptide subunits that show formation of specific secondary structure

A family of novel oligomers based on the anthranilamide nucleus has been prepared and shown to form well-defined secondary structural features. 1H NMR and X-ray crystallographic techniques have demonstrated that intramolecular hydrogen bonds play a key role in stabilizing both linear sheet and helical conformational forms.

Preparation and biological activity of 2-[4-(thiazol-2-yl)phenyl]propionic acid derivatives inhibiting cyclooxygenase

A series of 2-[4-(thiazol-2-yl)phenyl]propionic acids substituted at various positions were prepared by the reaction of diethyl 2-methyl-2-(4-thiocarbamoylphenyl)malonates with α-bromoaldehyde diethyl acetals or α-haloketones followed by hydrolysis of esters. The inhibition of prostaglandin H synthetase (cyclooxygenase) was assayed by use of an enzyme preparation from guinea pig polymorphonuclear leukocytes. Examination of the structure-activity relationship of these compounds indicated that the substitution pattern with halogens at position 3 (R1) of the benzene ring and a methyl group in position 4 (R2) and/or 5 (R3) of the thiazole ring were favorable for inhibitory activity. The compounds bearing bulky alkyl or polar functional groups at the R2 position were weak inhibitors. The potent inhibitors of cyclooxygenase were tested for their ability to reduce carrageenin-induced inflammation of rat paws. These derivatives had strong anti-inflammatory activity based on their strong inhibition of cyclooxygenase, with some exceptions, including those with a thiomethyl group at R1.

Addition of nitroalkanes toortho-halonitrobenzenes: A new synthesis of 4-chloro-7-(trifluoromethyl)quinoline

Base-mediated reaction of ortho-nitroaryl chlorides and fluorides with nitroalkanes followed by an oxidative Nef reaction provides aryl ketones. With this simple procedure, methylketone 6 was prepared in 91% yield. 6 was then converted in three steps (60-65% yield) to 4-chloro-7-(trifluoromethyl)quinoline (2), an intermediate in the synthesis of the antihypertensive agent losulazine (U-54,669, 1).